☰ Show/Hide Menu

MorphoSys's
therapeutic pipeline

You are here

  1. Home
  2. Pipeline

With currently more than 100 distinct drugs in research and development, MorphoSys has one of the broadest pipelines in the biotechnology industry, including unique approaches that aim to help patients with conditions such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.

More than 20 therapeutic antibodies are being evaluated by MorphoSys and its partners in clinical trials as novel treatment options for severe and in many cases life-threatening diseases. Several of these in-house and partnered programs have already demonstrated exciting prospects for diseases where currently no proper treatment is available.
MorphoSys continues to expand its portfolio of unique drug candidates and is looking for partners with innovative targets, supportive technologies and promising antibodies for further development.

 

Clinical Pipeline

  • Proprietary Programs
  • Partnered Programs
  • Phase 1
  • Phase 2
  • Phase 3
  • Market
29 Antibodies available:
Program
Partner
Indication
Phase

MOR208

Partner

Not partnered

Indication

Phase

Diffuse large B cell lymphoma (DLBCL) (B-MIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Diffuse large B cell lymphoma (DLBCL) (L-MIND)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Chronic lymphocytic leukemia (CLL) (IIT study)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

In June 2010, MorphoSys AG and US-based biopharmaceutical company Xencor signed a worldwide exclusive license and collaboration agreement for the antibody. The agreement provided MorphoSys with an exclusive worldwide license to XmAb5574 for the treatment of cancer and other indications.

More Information on MOR208

MOR202

Partner

Not partnered

Indication

Phase

Multiple myeloma (MM)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.  Either Velcade® (bortezomib) or Revlimid® (lenalidomide) enhanced the cytotoxic activity of MOR202 in vitro and also the inhibition of MM-mediated bone lysis and tumor load in vivo. The enhancement by bortezomib was mediated through a direct cytotoxic effect on MM cells.

Lenalidomide synergistically enhanced MOR202 activity by several mechanisms identified to be direct cytotoxicity, activation of effector cells and increased CD38 expression levels on MM cells. In an orthotopic xenograft murine model of multiple myeloma, MOR202 reduced tumor load and tumor mediated bone lysis. Co-administration of MOR202 with either bortezomib or lenalidomide completely abolished bone lysis in a synergistic manner. These findings support further investigation of MOR202 combination regimens in clinical trials. MOR202 is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.

More Information on MOR202

MOR103/GSK3196165

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid arthritis (RA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis (RA) (mechanistic study)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hand osteoarthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis (RA, Japan)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases, i.e. rheumatoid arthritis, where current treatment options are inadequate. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline.

More Information on MOR103/GSK3196165

MOR209/ES414

Partner

Aptevo Therapeutics

Indication

Phase

Prostate cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The immunotherapeutic protein activates the patients’ T-cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor.

MOR209/ES414 is part of MorphoSys’s collaboration with Aptevo Therapeutics (formaly Emergent BioSolutions) to jointly develop the compound.

More information on MOR209/ES414

MOR106

Partner

Galapagos

Indication

Phase

Atopic dermatitis
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases. MOR106 arises from the alliance initiated by Galapagos and MorphoSys in 2008, in which both companies contribute their core technologies and expertise. Galapagos and MorphoSys will continue to equally share the research and development costs, as well as all future revenues.

More information on MOR106

MOR107

Partner

Not partnered

Indication

Phase

Undisclosed
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR107 (formerly LP2-3), a selective agonist of the angiotensin II receptor type 2, is a lanthipeptide based on Lanthio Pharma’s proprietary technology platform. Currently MOR107 is investigated in a “first-in-human” clinical study in healthy volunteers.

More Information on MOR107

Guselkumab

Partner

Janssen/J&J

Indication

Phase

Plaque psoriasis (VOYAGE 1)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Plaque psoriasis (VOYAGE 2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Plaque psoriasis (NAVIGATE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Pustular/Eerythrodermic psoriasis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Plaque psoriasis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Plaque psoriasis (POLARIS)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Palmoplantar pustulosis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Moderate to severe plaque psoriasis (efficacy & safety)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Moderate to severe plaque psoriasis (comparative efficacy)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriatic arthritis (PsA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

More Information on Guselkumab

Gantenerumab

Partner

Roche

Indication

Phase

Mild Alzheimer's disease (Marguerite RoAD)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer´s disease
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Genetically predisposed for Alzheimer's disease (DIAN)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Safety, tolerability, and pharmacokinetics (sc)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Pain, tolerability, safety and pharmacokinetics (sc)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Amyloid-beta

Additional Information:

More Information on Gantenerumab

Anetumab Ravtansine

Partner

Bayer AG

Indication

Phase

Mesothelioma (MPM)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Pancreatic cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced malignancies (Japan)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Ovaria cancer (combo with doxorubicin)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with pemetrexed & cisplatin)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors with hepatic / renal impairment
Phase 1 (Current Phase) Phase 2 Phase 3 Market
ECG & drug interaction (combo with itraconazole)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

BHQ880

Partner

Novartis

Indication

Phase

Multiple myeloma (MM) (renal insufficiency)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Smoldering multiple myeloma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Dickkopf-1 (DKK-1)

Additional Information:

Bimagrumab

Partner

Novartis

Indication

Phase

Muscular atrophy after hip fracture surgery
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Sarcopenia (dose-ranging)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Sarcopenia (withdrawal extension study)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Type 2 diabetes
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

BPS804

Partner

Novartis/Mereo

Indication

Phase

Osteoporosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hypophosphatasia (HPP)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Brittle bone disease
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Brittle bone disease (Type I, III, IV)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: Sclerostin

Additional information:

CNTO3157

Partner

Janssen/J&J

Indication

Phase

Asthma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Safety and pharmacokinetics
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody

Additional Information:

CNTO6785

Partner

Janssen/J&J

Indication

Phase

Chronic obstructive pulmonary disease (COPD)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis (RA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody

Additional Information:

Elgemtumab (LJM716)

Partner

Novartis

Indication

Phase

ESCC (combo with BYL719)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
HER2+ cancer (combo with BYL719 & trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
HER2+ cancer (combo with trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: HER3

Additional information:

Tesidolumab (LFG316)

Partner

Novartis

Indication

Phase

Age-related geographic atrophy
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Geographic atrophy (combo with CLG561)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Panuveitis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Paroxysmal nocturnal hemoglobinuria
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Transplant associated microangiopathy (TAM)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Renal disease patients awaiting kidney transplant
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: C5

Additional Information:

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Solid tumors (JAVELIN Medley) (combo with avelumab)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors, NHL (combo with rituximab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with pembrolizumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with mogamulizumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with PF-04518600)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Diffuse large B cell lymphoma (DLBCL) (combo with avelumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

VAY736

Partner

Novartis

Indication

Phase

Pemphigus vulgaris
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Primary Sjögren's syndrome
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis (RA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Primary Sjögren's syndrome (efficacy & safety)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: BAFF-R

Additional information:

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors (Japan)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with abemaciclib)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
EGFR mutant non-small cell lung cancer (NSCLC)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IGF-1

Additional Information:

BAY1093884

Partner

Bayer AG

Indication

Phase

Hemophilia
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: tissue factor pathway inhibitor (TFPI)

Additional information:

NOV-7

Partner

Novartis

Indication

Phase

Eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-8

Partner

Novartis

Indication

Phase

Inflammation
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-9

Partner

Novartis

Indication

Phase

Diabetic eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-10

Partner

Novartis

Indication

Phase

Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-11

Partner

Novartis

Indication

Phase

Blood disorders
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-12

Partner

Novartis

Indication

Phase

Prevention of thrombosis
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-13

Partner

Novartis

Indication

Phase

Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-14

Partner

Novartis

Indication

Phase

Asthma
Phase 1 (Current Phase) Phase 2 Phase 3 Market

Vantictumab (OMP-18R5)

Partner

OncoMed

Indication

Phase

Breast cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Pancreatic cancer (combo)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Non-small-cell lung carcinoma (NSCL)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Wnt signaling pathway (Fzd 7)
  • Alias: OMP-18R5

Additional information:

Additionally, MorphoSys currently has various proprietary and partnered programs in the discovery or preclinical phase (December 31, 2016: 62 programs in discovery, 23 programs in preclinic)